Info

Bionovo, Inc. (Bionovo) is a clinical stage drug discovery and development company focusing on women’s health and cancer. The Company’s lead drug candidate, MF101, represents a class of receptor sub-type selective estrogen receptor modulator for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed MF101 to selectively modulate estrogen receptor beta. In preclinical studies, MF101 inhibited tumor growth as well as bone resorption known to cause osteoporosis, is commonly developed during menopause. In its completed, randomized, placebo-controlled Phase II trial involving 217 patients for, which it announced results during the year ended December 31, 2007, the higher of two MF101 doses tested was well tolerated and resulted in a statistically significant reduction of hot flashes when compared to placebo at 12 weeks of treatment, comparable to existing non-hormonal therapies. Bionova has identified BZL101 a anti-cancer agent for advanced breast cancer.(Source: 10-K)